TriSalus Life Sciences, Inc 8-K, filed Jun 16, 2025
TriSalus Life Sciences, Inc. (TLSI)
8-K
2025-06-16
For: 2025-06-12
View Original
Added on
April 07, 2026
About this 8-K
TriSalus Life Sciences, Inc filed this 8-K on June 16, 2025, reporting on events of June 12, 2025.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 12, 2025
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
(Registrant's telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: | |||||
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
| Item 5.07 | Submission of Matters to a Vote of Security Holders. | |||||||
On June 12, 2025, TriSalus Life Sciences, Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Meeting”).
Of the 36,180,828 total shares of common stock of the Company that were issued and outstanding on April 17, 2025, the record date for the Meeting, 26,482,799 shares, constituting 73.2% of the total outstanding shares, were represented in person or by proxy at the Meeting. The matters voted upon at the Annual Meeting and the results of such voting are set forth below based on the information we received on the day of the meeting from our vote tabulator, Broadridge Investor Communications.
1.The two nominees for Directors were elected to serve three-year terms to expire at the annual meeting of shareholder in 2028, as follows:
| Nominee | For | Against | Abstain | Broker Non-Votes | ||||||||||||||||||||||
| Mats Wahlström | 20,002,109 | — | 501,937 | 5,978,753 | ||||||||||||||||||||||
| David J. Matlin | 20,005,151 | — | 498,895 | 5,978,753 | ||||||||||||||||||||||
2.The appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the year 2025 was ratified by the shareholder vote:
| For | Against | Abstain | ||||||||||||
| 26,445,528 | 36,277 | 994 | ||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 16, 2025 | TriSalus Life Sciences, Inc. | ||||||||||
| By: | /s/ Mary Szela | ||||||||||
| Name: | Mary Szela | ||||||||||
| Title: | Chief Executive Officer | ||||||||||